A Favorable View: Progress in Cancer Prevention and Screening

  • Peter Greenwald
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 174)

Abstract

Clifton Leaf, in his article “Why We’re Losing the War on Cancer,” presents criticisms of past research approaches and the small impact of this research thus far on producing cures or substantially extending the life of many cancer patients. It is true that gains in long-term survival for people with advanced cancers have been modest, hindered in part by the heterogeneity of tumors, which allows the cancers to persist using alternate molecular pathways and so evade many cancer therapeutics. In contrast, clinical trials have demonstrated that it is possible to reduce the incidence or improve cancer survival through prevention and early detection. Strides have been made in preventing or detecting early the four deadliest cancers in the United States (i.e., lung, breast, prostate, and colorectal). For example, 7-year follow-up data from the Breast Cancer Prevention Trial (BCPT) provides evidence that tamoxifen reduces the occurrence of invasive breast tumors by more than 40%; recent studies using aromatase inhibitors and raloxifene are also promising. The Prostate Cancer Prevention Trial (PCPT) showed that finasteride reduced prostate cancer incidence by 25%, and the ongoing Selenium and Vitamin E Cancer Prevention Trial (SELECT) is investigating selenium and vitamin E for prostate cancer prevention based on encouraging results from earlier studies. Living a healthy lifestyle, including regular physical activity, avoiding obesity, and eating primarily a plant-based diet has been associated with a lower risk of colorectal cancer. In addition, noninvasive stool DNA tests for early detection are being studied, which may lessen the reluctance of people to be screened for colorectal polyps and cancer. Behavioral and medical approaches for smoking prevention are ways to reduce the incidence of lung cancer, with antinicotine vaccines on the horizon that may help former smokers to avoid relapse. The US National Lung Screening Trial is testing whether early detection via spiral CT screening will reduce lung cancer mortality. Prevention and earlier detection offer efficient and practical strategies to reduce the cancer burden. Several of the suggestions Mr. Leaf makes, such as developing interdisciplinary collaborations and allocating resources to research earlier in the process of carcinogenesis, have become an integral strategy in the National Cancer Institute’s (NCI) approach in the past decade, specifically in the realm of cancer prevention and early detection. For example, an aggressive program to identify biomarkers for earlier detection of cancer — the NCI’s Early Detection Research Detection (EDRN) — has identified three promising biomarkers since its establishment in 2000. It collaborates with the National Institute of Standards and Technology and extramural scientists to develop validation standards and to identify the best technologies to use for systematic investigations. If these biomarkers can be validated, they might help to reduce cancer mortality.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Cancer Society. http://www.cancer.org/docroot/home/index.asp. Accessed 30 January 2006Google Scholar
  2. Agrawal A, Gutteridge E, Gee JM, Nicholson RI, Robertson JF (2005) Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer 12[Suppl 1]:S135–S144PubMedCrossRefGoogle Scholar
  3. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029–1035CrossRefGoogle Scholar
  4. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139PubMedCrossRefGoogle Scholar
  5. Brawley OW, Ford LG, Thompson I, Perlman JA, Kramer BS (1994) 5-Alpha-reductase inhibition and prostate cancer prevention. Cancer Epidemiol Biomarkers Prev 3:177–182PubMedGoogle Scholar
  6. Burns DM (2000) Primary prevention, smoking, and smoking cessation: implications for future trends in lung cancer prevention. Cancer 89:2506–2509PubMedCrossRefGoogle Scholar
  7. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638PubMedCrossRefGoogle Scholar
  8. Campbell MJ, Gombart AF, Kwok SH, Park S, Koef-fler HP (2000) The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene 19:5091–5097PubMedCrossRefGoogle Scholar
  9. Cerny T (2005) Anti-nicotine vaccination: where are we? Recent Results Cancer Res 166:167–175PubMedGoogle Scholar
  10. Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL (1999) Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 8:893–899PubMedGoogle Scholar
  11. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL, Taylor JR (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276:1957–1963PubMedCrossRefGoogle Scholar
  12. COMMIT Research Group (1991) Community Intervention Trial for Smoking Cessation (COMMIT): summary of design and intervention. J Natl Cancer Inst 83:1620–1628CrossRefGoogle Scholar
  13. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197PubMedCrossRefGoogle Scholar
  14. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN, Pickle LW (2005) Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Nat Cancer Inst 97:1407–1427PubMedCrossRefGoogle Scholar
  15. Efuet ET, Keyomarsi K (2006) Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome. Cancer Res 66:1040–1051PubMedCrossRefGoogle Scholar
  16. Feigl P, Blumenstein B, Thompson I, Crowley J, Wolf M, Kramer BS, Coltman CA Jr, Brawley OW, Ford LG (1995) Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials 16:150–163PubMedCrossRefGoogle Scholar
  17. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479–484PubMedCrossRefGoogle Scholar
  18. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388PubMedCrossRefGoogle Scholar
  19. Fisher B, Jeong JH, Anderson S, Wolmark N (2004) Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst 96:1823–1831PubMedCrossRefGoogle Scholar
  20. Fleming J, Ghose A, Harrison PR (2001) Molecular mechanisms of cancer prevention by selenium compounds. Nutr Cancer 40:42–49PubMedCrossRefGoogle Scholar
  21. Furr BJ, Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127–205PubMedCrossRefGoogle Scholar
  22. Furuya Y, Ohta S, Shimazaki J (1996) Induction of apoptosis in androgen-independent mouse mammary cell line by 1, 25-dihydroxyvitamin D3. Int J Cancer 68:143–148PubMedCrossRefGoogle Scholar
  23. Giger ML (2004) Computerized analysis of images in the detection and diagnosis of breast cancer. Semin Ultrasound CT MR 25:411–418PubMedCrossRefGoogle Scholar
  24. Giovannucci E (1998) Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control 9:567–582PubMedCrossRefGoogle Scholar
  25. Gohagan J, Marcus P, Fagerstrom R, Pinsky P, Kramer B, Prorok P (2004) Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute. Chest 126:114–121PubMedCrossRefGoogle Scholar
  26. Grau MV, Baron JA, Sandler RS, Haile RW, Beach ML, Church TR, Heber D (2003) Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst 95:1765–1771PubMedGoogle Scholar
  27. Greenwald P, Clifford CK (1995) Dietary prevention. In: Greenwald P, Kramer BS, Weed DK (eds) Cancer Prevention and Control. Marcel Dekker, New York, pp 302–327Google Scholar
  28. Greenwald P, Kramer B, Weed D (1993) Expanding horizons in breast and prostate cancer prevention and early detection. The 1992 Samuel C. Harvey Lecture. J Cancer Educ 8:91–107PubMedCrossRefGoogle Scholar
  29. Heber D, Lu QY (2002) Overview of mechanisms of action of lycopene. Exp Biol Med 227:920–923Google Scholar
  30. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, Coltman C (2001) SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. J Urol 166:1311–1315PubMedCrossRefGoogle Scholar
  31. Lam S, MacAulay C, Le Riche JC, Dyachkova Y, Coldman A, Guillaud M, Hawk E, Christen MO, Gazdar AF (2002) A randomized phase IIb trial of anethole dithiolthione in smokers with bronchial dysplasia. J Natl Cancer Inst 94:1001–1009PubMedGoogle Scholar
  32. Leaf C (2004) Why we’re losing the war on cancer (and how to win it). Fortune 149:76–82, 84–6, 88 passimPubMedGoogle Scholar
  33. McCann SE, Moysich KB, Freudenheim JL, Ambrosone CB, Shields PG (2002) The risk of breast cancer associated with dietary lignans differs by CYP17 genotype in women. J Nutr 132:3036–3041PubMedGoogle Scholar
  34. Miller EC, Giovannucci E, Erdman JW Jr, Bahnson R, Schwartz SJ, Clinton SK (2002) Tomato products, lycopene, and prostate cancer risk. Urol Clin North Am 29:83–93PubMedCrossRefGoogle Scholar
  35. Milner JA, McDonald SS, Anderson DE, Greenwald P (2001) Molecular targets for nutrients involved with cancer prevention. Nutr Cancer 41:1–16PubMedCrossRefGoogle Scholar
  36. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS (1991) Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83:1450–1459PubMedCrossRefGoogle Scholar
  37. Nomura AM, Lee J, Stemmermann GN, Combs GF Jr (2000) Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 9:883–887PubMedGoogle Scholar
  38. Overmoyer BA (1999) The breast cancer prevention trial (P-1 study). The role of tamoxifen in preventing breast cancer. Cleve Clin J Med 66:33–40PubMedGoogle Scholar
  39. Page GP, Green JL, Lackland D (2000) Epidemiology of lung cancer with special reference to genetics, bioassays, women, and developing countries. Semin Respir Crit Care Med 21:365–373PubMedCrossRefGoogle Scholar
  40. Poole C (2004) Adjuvant chemotherapy for early-stage breast cancer: the tAnGo trial. Oncology (Williston Park) 18:23–26Google Scholar
  41. Potter JD, Finnegan JR, Guinard JX (2000) 5-A-Day for Better Health Program evaluation report. NIH Publication No. 01-4904. Bethesda, MD, National Institutes of Health, National Cancer InstituteGoogle Scholar
  42. Regueiro CR (2005) AGA Future Trends Committee report: colorectal cancer: a qualitative review of emerging screening and diagnostic technologies. Gastroenterology 129:1083–1103PubMedCrossRefGoogle Scholar
  43. Rittmaster RS (1994) Finasteride. N Engl J Med 330:120–125PubMedCrossRefGoogle Scholar
  44. Rochefort H, Glondu M, Sahla ME, Platet N, Garcia M (2003) How to target estrogen receptor-negative breast cancer? Endocr Relat Cancer 10:261–266PubMedCrossRefGoogle Scholar
  45. Smith JA, Andreopoulou E (2004) An overview of the status of imaging screening technology for breast cancer. Ann Oncol 15[Suppl 1]:I18–I26PubMedCrossRefGoogle Scholar
  46. Stillman FA, Hartman AM, Graubard BI, Gilpin EA, Murray DM, Gibson JT (2003) Evaluation of the American Stop Smoking Intervention Study (ASSIST): a report of outcomes. J Natl Cancer Inst 95:1681–1691PubMedGoogle Scholar
  47. Thompson IM, Tangen C, Goodman P (2003) The Prostate Cancer Prevention Trial: design, status, and promise. World J Urol 21:28–30PubMedGoogle Scholar
  48. U.S. Department of Health and Human Services (2001) Women and Smoking: A Report of the Surgeon General. U.S. Department of Health and Human Services, Public Health Service, Office of the Assistant Secretary for Health, Office on Smoking and Health, Washington, DCGoogle Scholar
  49. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N (2002) The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer 3:153–159PubMedCrossRefGoogle Scholar
  50. Wakeling AE (2005) Inhibitors of growth factor signalling. Endocr Relat Cancer 12[Suppl 1]:S183–S187PubMedCrossRefGoogle Scholar
  51. Wargovich MJ, Cunningham JE (2003) Diet, individual responsiveness and cancer prevention. J Nutr 133:2400S–2403SPubMedGoogle Scholar
  52. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, Edwards BK (2003) Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Nat Cancer Inst 95:1276–1299PubMedGoogle Scholar
  53. Winawer SJ, Zauber AG, Ho MN, O’Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF (1993) Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329:1977–1981PubMedCrossRefGoogle Scholar
  54. Yoshizawa K, Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, Giovannucci E (1998) Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 90:1219–1224PubMedCrossRefGoogle Scholar
  55. Zeng H, Davis CD, Finley JW (2003) Effect of selenium-enriched broccoli diet on differential gene expression in min mouse liver(1,2). J Nutr Biochem 14:227–231PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2007

Authors and Affiliations

  • Peter Greenwald
    • 1
  1. 1.Division of Cancer Prevention National Cancer InstituteNational Institutes of HealthBethesdaUSA

Personalised recommendations